GLP-1 & obesity peptides: the complete class guide
This page groups every compound being developed or used for weight loss through the incretin and amylin hormone systems, whether it is a true GLP-1 receptor agonist, a dual or triple agonist, or an amylin analog with no GLP-1 activity at all. Some are FDA-approved; most are still in clinical trials. Each entry links to its own full write-up with dosage data, evidence tiers, and sources.
Ask PeptideBlog about any peptide
Approved
Cleared by the FDA and in general clinical use.
| Compound | Mechanism | Status | Developer / brand |
|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Approved | Novo Nordisk (Ozempic, Wegovy) |
| Tirzepatide | GIP/GLP-1 dual agonist | Approved | Eli Lilly (Mounjaro, Zepbound) |
| Liraglutide | GLP-1 receptor agonist | Approved | Novo Nordisk (Victoza, Saxenda) |
| Pramlintide | Amylin analog | Approved | Approved for diabetes (Symlin); amylin-class origin point |
| Orforglipron | Oral non-peptide GLP-1 agonist | Approved | Eli Lilly (Foundayo; US approval for chronic weight management, April 2026) |
A recent Italian cohort study reported higher heart attack, stroke and death rates in time spent after stopping a GLP-1 drug. The GLP-1 discontinuation and mortality analysis covers why a hazard ratio of 4.81 is not a risk multiple.
Late-stage investigational
In Phase 2 or Phase 3 trials, or approved in one market and still investigational elsewhere.
| Compound | Mechanism | Status | Developer |
|---|---|---|---|
| Retatrutide | GIP/GLP-1/glucagon triple agonist | Phase 3 | Eli Lilly |
| Cagrilintide | Long-acting amylin analog | Phase 3 | Novo Nordisk (paired with semaglutide as CagriSema) |
| Survodutide | GLP-1/glucagon dual agonist | Phase 3 | Boehringer Ingelheim / Zealand Pharma |
| Mazdutide | GLP-1/glucagon dual agonist | Phase 3 / approved in China | Innovent Biologics / Eli Lilly |
| VK2735 | GIP/GLP-1 dual agonist (injectable and oral) | Phase 3 | Viking Therapeutics |
| Amycretin | GLP-1/amylin dual agonist | Phase 2/3 | Novo Nordisk |
| Pemvidutide | GLP-1/glucagon dual agonist | Phase 2 | Altimmune |
| Enicepatide (CT-388) | GIP/GLP-1 dual agonist | Phase 2 | Roche (via Carmot Therapeutics) |
| MariTide (maridebart cafraglutide) | GIP/GLP-1 receptor bispecific | Phase 3 (MARITIME program) | Amgen |
| GSBR-1290 (aleniglipron) | Oral non-peptide GLP-1 receptor agonist | Phase 2b | Structure Therapeutics |
| AZD5004 (elecoglipron) | Oral non-peptide GLP-1 receptor agonist | Phase 2 published, Phase 3 planned | AstraZeneca |
| RGT-075 | Oral non-peptide GLP-1 receptor agonist | Phase 2b | Regor Therapeutics |
| Danuglipron | Oral non-peptide GLP-1 receptor agonist | Discontinued (Apr. 2025, liver-injury signal) | Pfizer |
| Eloralintide | Amylin analog | Phase 3 | Eli Lilly |
Early investigational
Earlier-phase candidates with limited public data so far.
| Compound | Mechanism | Status | Developer |
|---|---|---|---|
| Petrelintide | Long-acting amylin analog | Phase 3 | Zealand Pharma |
| UBT251 | GIP/GLP-1/glucagon triple agonist | Early-to-mid phase (status disputed across sources) | United Biotechnology |
| Nisotirostide | Investigational incretin-class candidate | Early phase | Not yet disclosed |
| NBIP-1968 | Investigational incretin-class candidate | Early phase | Not yet disclosed |
| TERN-601 | Oral non-peptide GLP-1 receptor agonist | Phase 2 (topline reported) | Terns Pharmaceuticals |
| CT-996 | Oral non-peptide GLP-1 receptor agonist | Phase 2, positive Phase 1 | Roche (via Carmot Therapeutics) |
| Dapiglutide | GLP-1/GLP-2 dual agonist | Paused (positive Phase 1b, program paused for pipeline priorities) | Zealand Pharma |
Also see: brenipatide, a Lilly GIP/GLP-1 agonist in phase 3 for alcohol use disorder and depression rather than weight loss, the retatrutide entry for the triple-agonist data, and our write-up on LY4086940, an oral Lilly compound in two registered trials.
Related reading: not every obesity candidate is a peptide. See how strong the evidence is for TOFA, a non-peptide metabolic compound studied in mice, and what human data is still missing. Another non-peptide, CBL-514, is an injectable studied for local abdominal fat rather than weight loss, and the article covers what its trials did and did not measure.
The amylin side of the class has its own comparison: petrelintide, eloralintide and cagrilintide compared, including the ZUPREME trial results. For the amounts and schedules reported for petrelintide, see the petrelintide dosage guide.
Brand names in this class are still moving. Eli Lilly holds live US trademark applications for Retzoundi and Retkouro, both filed on April 23, 2024, and has not said which medicine, if any, they are meant for. Posts online link them to retatrutide, but the filings name no drug. Our Retzoundi and Retkouro write-up sets out what the records show and what they leave out.
This is a compilation of publicly available information for educational reference, not medical advice, and not a recommendation to use any of these compounds. Approval and trial status change frequently, so check each compound’s own entry for the most current sourced detail.
Foundayo (orforglipron) is the oral small-molecule option in this class. Its dose ladder and capsule-to-tablet map are tabled in the orforglipron dosage guide.
Reported amounts and schedules for the main compounds in this class are tabled in separate dosage guides: semaglutide dosage, tirzepatide dosage, retatrutide dosage and cagrilintide dosage. Each one keeps published trial amounts separate from figures circulating online and names the source. For how these and other peptides are treated in compounding, see the FDA peptide status guide.
For how a single oral GLP-1 headline number is built, and why it cannot be ranked against other trials, see what the CX11 11.5% weight loss figure measures.